Za a iya Takama Omega-3 Taimako na Sclerosis Mai Girma?

Amfani da Shaida ta yanzu

Idan kun kasance tare da ƙwayar sclerosis (MS) na dan lokaci, watakila sun ji ko karanta rahotanni game da amfanin omega-3 acid a cikin maganin cutar. Duk da yake mun rigaya san cewa wadannan "mai lafiya" sunada mana kyau, shin suna da wani tasiri a kan ko dai suna kawar da bayyanar cututtuka (kamar gajiya ko ɓacin zuciya) ko kuma rage yawan ƙananan ciwon da ke cikin ɓangaren cutar?

Sanin Omega-3 Fatty Acids

Idan yazo wajen cinye kayan abinci daga abincinku, wanda ba ku so ya sake dawowa shi ne omega-3 fatty acid. Ba kamar "mummunan" kwayoyi ba ko masu fashi, omega-3 shine fatadden da aka sani da ƙananan triglycerides, tada "kyakkyawan" HDL cholesterol, da inganta wasu ayyuka na kwakwalwa.

Bugu da ƙari, omega-3 fatty acid ya ƙunshi biyu mahadi, eicosapentaeno acid (EPA) da kuma docosahexaenoic acid (DHA), wanda aka yi imanin cewa rage wasu martani a cikin jiki. Wannan shi ne dalilin da ya sa sau da yawa an kara kariyar kayan karaga-3 tare da halayyar maganin arthritis na rheumatoid .

Tun da MS ta kasance mummunan cututtuka wadda ke haifar da lalacewa cikin tsarin kulawa na tsakiya, masana kimiyya sun dade da yawa sunyi nazarin zaton cewa fatty acid din mai-omega-3 na iya shawo kan cigaba da / ko tsananin cutar.

Sources na Omega-3 Fatty Acids

Jiki na iya haifar da ƙwayoyi masu yawa da ya buƙaci daga wasu ƙwayoyi ko matakan sinadaran.

Omega-3 acid mai daraja, da bambanci, an dauke su da hatsi mai mahimmanci, ma'anar cewa zaka iya samun su daga abincin da ke dauke da su. Wadannan sun haɗa da:

Har ila yau, akwai karin kariyar omega-3 wanda aka samu a ko dai kwaya ko siffar ruwa. (Yi magana da likitanku kafin daukar wani karin omega-3 kamar yadda zai iya hulɗa tare da masu zubar da jini da sauran magungunan magunguna wanda za ku iya ɗauka.)

Sakamakon binciken

Baya ga amfanin lafiyar kiwon lafiya na Omega-3, akwai shawarwari da cewa ƙara yawan ciwa zai iya yakin da MS. Anyi amfani da maganganu a farkon bincike wanda ya nuna cewa omega-3 zai iya hana wasu sunadaran (wanda ake kira matrix-metalloproteinase-9) da aka sani don haifar da kumburi a cikin tsarin kulawa na tsakiya.

Bugu da kari, wasu wurare na bincike sun fara nuna bayanan lissafin cewa omega-3 zai iya taimakawa wajen magance matsalolin babban ciki har da wasu cututtuka irin su lupus , cututtukan Crohn , ulcerative colitis , da arthritis rheumatoid.

Yayinda yake fahimta cewa MS-wata cuta tare da halayen motsa jiki wanda abin da yake ciki shi ne wani ɓangare na kowa-na iya amsawa a cikin wannan salon, yawancin bincike ya haɗa:

Opin binciken binciken Omega-3

Bambancin yanayin bincike ya nuna cewa acid mai-omega-3, yayin da yake da amfani ga lafiyar mu na zuciya, na iya samun tasiri akan cigaba ko alamar MS.

Akwai wasu da suka yi imani da cewa yawancin da aka yi amfani da su a cikin intravenously iya inganta waɗannan sakamakon, amma mafi yawan sun kasance masu shakka saboda sakamakon mummunar haɓaka omega-2 (ciki har da zuciya mai maɗaukaki, anemia, da hangen nesa).

Duk da haka, wannan bai kamata ya rage yawan amfanin omega-3 ba a cikin abincinmu idan dai don tabbatar da jikin mu da karfi da kuma mafi kyawun iya magance kalubale na sclerosis.

Sources:

> Hoare, S .; Lithander, F .; van der Mei, I. et al. "Yin amfani da hakar omega-3 mai yawan sinadarai mai haɗari yana haɗuwa da ƙananan haɗari na asalin binciken asibiti na farko na juyayi mai yawa: Sakamako daga Nazarin Ausimmune." Mult Scler . 2016; 22 (7): 884-92.

> Shinto, L; Maracci, G .; Bumgardner, L. et al. "Hanyoyi na Omega-3 Fatty Acids a Matrix Metalloproteinase-9 Gidajen Shirin Halitta da Tsuntsaye a Tsarin Kwayoyin Halitta na Mutum: Abubuwan Dama ga Sclerosis Mai Girma." Autoimmune Dis. 2011; 2011: 134592.

> Shinto, L; Maracci, G .; Mohr, D. et al. "Omega-3 Fatty Acids for Depression in Multiple Sclerosis: Wani Nazarin Hidimar Nazari." PLoS. 2016; DOI 10.1371 / journa.pone.0147195.

> Torkildsen, Ya. Wergeland, S .; Bakke, S. et al. " ω-3 Fatty Acid Jiyya a Multiple Sclerosis (binciken OFAMS): A Randomized, Double-Blind, Testing Controlled Control." Arch Neurol. 2012; 69 (8): 1044-1051.